These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16460844)

  • 21. Substitutions near the hemagglutinin receptor-binding site determine the antigenic evolution of influenza A H3N2 viruses in U.S. swine.
    Lewis NS; Anderson TK; Kitikoon P; Skepner E; Burke DF; Vincent AL
    J Virol; 2014 May; 88(9):4752-63. PubMed ID: 24522915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating Vaccine-Driven Selection in Seasonal Influenza.
    Wen FT; Bell SM; Bedford T; Cobey S
    Viruses; 2018 Sep; 10(9):. PubMed ID: 30231576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterizing genetic and antigenic divergence from vaccine strain of influenza A and B viruses circulating in Thailand, 2017-2020.
    Suntronwong N; Klinfueng S; Korkong S; Vichaiwattana P; Thongmee T; Vongpunsawad S; Poovorawan Y
    Sci Rep; 2021 Jan; 11(1):735. PubMed ID: 33437008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Influenza H3N2 Vaccine Efficacy From Evolution of the Dominant Epitope.
    Bonomo ME; Deem MW
    Clin Infect Dis; 2018 Sep; 67(7):1129-1131. PubMed ID: 29672670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain.
    Wan H; Gao J; Yang H; Yang S; Harvey R; Chen YQ; Zheng NY; Chang J; Carney PJ; Li X; Plant E; Jiang L; Couzens L; Wang C; Strohmeier S; Wu WW; Shen RF; Krammer F; Cipollo JF; Wilson PC; Stevens J; Wan XF; Eichelberger MC; Ye Z
    Nat Microbiol; 2019 Dec; 4(12):2216-2225. PubMed ID: 31406333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pandemic vaccine preparedness--have we left something behind?
    Capua I; Kajaste-Rudnitski A; Bertoli E; Vicenzi E
    PLoS Pathog; 2009 Jun; 5(6):e1000482. PubMed ID: 19557166
    [No Abstract]   [Full Text] [Related]  

  • 27. [Characteristics of epidemiological strains of influenza A virus (H3N2) isolate in 1997-1999. Virus A/Moscow/10/99--a candidate to become the vaccine strain].
    Slepushkin AN; Ivanova VT; Burtseva EI; Oskerko TA; Volodina TN; Kuribko SG; Kolobukhina LV; Beda MV
    Vopr Virusol; 2000; 45(4):22-4. PubMed ID: 10971961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigenic and genetic variation in the hemagglutinins of H1N1 and H3N2 human influenza a viruses in the Shanghai area from 2005 to 2008.
    Ren XW; Ju LW; Yang JX; Lv XH; Jiang LF; Zhao NQ; Jiang QW
    J Med Virol; 2011 Jul; 83(7):1113-20. PubMed ID: 21520138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of influenza vaccine immunogenicity using influenza antigen microarrays.
    Price JV; Jarrell JA; Furman D; Kattah NH; Newell E; Dekker CL; Davis MM; Utz PJ
    PLoS One; 2013; 8(5):e64555. PubMed ID: 23734205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Approaches for The Development of Live Attenuated Influenza Vaccines.
    Blanco-Lobo P; Nogales A; Rodríguez L; Martínez-Sobrido L
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30813325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.
    Zost SJ; Parkhouse K; Gumina ME; Kim K; Diaz Perez S; Wilson PC; Treanor JJ; Sant AJ; Cobey S; Hensley SE
    Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12578-12583. PubMed ID: 29109276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of antigenic cartography in vaccine seed strain selection.
    Fouchier RA; Smith DJ
    Avian Dis; 2010 Mar; 54(1 Suppl):220-3. PubMed ID: 20521635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antigenic and genomic relation between human influenza A (H3N2) viruses circulating in Argentina during 1998 and the H3N2 vaccine component.
    Pontoriero AV; Baumeister EG; Campos AM; Savy VL; Lin YP; Hay AJ
    Rev Panam Salud Publica; 2001 Apr; 9(4):246-53. PubMed ID: 11418972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the antineuraminidase antibody response to vaccination with intact virus and subunit preparations obtained by different techniques of the influenza virus strains A/Sing/1/57 (H2N2), A/Hong Kong/1/68 (H3N2) and A/Port Chalmers/1/73 (H3N2).
    Drescher J; Desselberger U
    Comp Immunol Microbiol Infect Dis; 1980; 3(1-2):219-23. PubMed ID: 6162604
    [No Abstract]   [Full Text] [Related]  

  • 35. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
    Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel M2e-multiple antigenic peptide providing heterologous protection in mice.
    Wen F; Ma JH; Yu H; Yang FR; Huang M; Zhou YJ; Li ZJ; Wang XH; Li GX; Jiang YF; Tong W; Tong GZ
    J Vet Sci; 2016 Mar; 17(1):71-8. PubMed ID: 27051342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modular epitope binding predicts influenza quasispecies dominance and vaccine effectiveness: Application to 2018/19 season.
    Bonomo ME; Kim RY; Deem MW
    Vaccine; 2019 May; 37(24):3154-3158. PubMed ID: 31060950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012-2013.
    Cobey S; Gouma S; Parkhouse K; Chambers BS; Ertl HC; Schmader KE; Halpin RA; Lin X; Stockwell TB; Das SR; Landon E; Tesic V; Youngster I; Pinsky BA; Wentworth DE; Hensley SE; Grad YH
    Clin Infect Dis; 2018 Jul; 67(3):327-333. PubMed ID: 29471464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model.
    Rosu ME; Kok A; Bestebroer TM; de Meulder D; Verveer EP; Pronk MR; Dekker LJM; Luider TM; Richard M; van den Brand JMA; Fouchier RAM; Herfst S
    J Virol; 2022 Mar; 96(6):e0195921. PubMed ID: 35107371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trial.
    Durviaux S; Treanor J; Beran J; Duval X; Esen M; Feldman G; Frey SE; Launay O; Leroux-Roels G; McElhaney JE; Nowakowski A; Ruiz-Palacios GM; van Essen GA; Oostvogels L; Devaster JM; Walravens K
    Clin Vaccine Immunol; 2014 Mar; 21(3):271-9. PubMed ID: 24371255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.